期刊文献+

甘肃地区前列腺癌的诊疗现状 被引量:1

The present status of diagnosis and treatment of prostate cancer in Gansu
下载PDF
导出
摘要 目的 探讨前列甘肃地区前列腺癌的诊疗现状。方法 以该地区3家省级医院2010年5月1日至2015年4月30日前列腺癌患者为研究对象,通过对患者发病年龄、血清前列腺特异性抗原(PSA)变化、发病特点、治疗方式、随访情况的分析,总结出该地区前列腺癌的诊疗情况。结果 5年来3家医院共计收治前列腺癌患者915例,年龄为38~96岁,平均71.2岁;血清PSA浓度〈4 ng/ml 49例,4~10 ng/ml 89例,10~20 ng/ml 44例,20~100 ng/ml 317例,〉100 ng/ml 416例;病理确诊患者879例,占96.1%;接受治疗患者882例,占96.4%,其中,药物内分泌治疗825例,占所有接受治疗患者的93.5%。根据血PSA值及转移灶情况,属于稳定期患者约占71%,有27%的患者属于进展期。在接受前列腺癌根治手术的患者中,80%患者无生化或临床复发,无1例死亡。结论 早期前列腺癌确诊成为治疗前列腺癌的主流,而内分泌治疗是前列腺癌的主要治疗方式。 Objective To study the current therapeutic status of prostate cancer in Gansu province,and provide evidence for the di-agnosis and treatment of prostatecancer in this area.Methods Patients with prostate cancer in 3 provincial hospitals of this region from May 1,2010 to April 30,2015 were selected.The onset age,serum PSA,clinical characteristic,treatment and follow-up of the situation were ana-lyzed.Results In five years,a total of 915 cases of patients with prostate cancer have been treated.The age ranges from 38 to 96 years old, the mean age is 71.2 years old.Serum PSA concentration 〈4 ng/ml was in 49 cases,4~10 ng/ml in 89 cases,10~20 ng/ml in 44 cases, 20~100 ng/ml in 317 cases,〉100 ng/ml in 416 cases.Among them,879 cases (96.1%)had pathological diagnosis;882 cases (96.4%) underwent treatment,of which 825 cases (93.5%)of patients were given endocrine treatment.According to the blood PSA and metastases lev-els,patients at stable stage was accounted for about 71%,advanced stage was accounted for about 27%.Among patients given radical prosta-tectomy surgery,80% of patients had no biochemical or clinical recurrence, no one died.Conclusions Early diagnosis and deterministic treatment of prostate cancer have become the mainstream,endocrine therapy is the main treatment of prostate cancer.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2016年第18期4573-4575,共3页 Chinese Journal of Gerontology
基金 国家自然科学基金(No.81302240) 兰州大学中央高校基本科研业务费(No.lzujbky-2013-134 lzujbky-2014-165) 甘肃省科技计划(No.145RJZA153)
关键词 前列腺癌 前列腺特异性抗原 内分泌治疗 根治性手术 Prostate cancer Prostate specific antigen Prostate biopsy Endocrine therapy Radical surgery
  • 相关文献

参考文献11

  • 1汪康宁,廖秋玲,陈烈钳,谭国斌,张高华,熊莽,柯龙志,张赛,陈合格.前列腺癌患者生存质量及影响因素分析[J].中国男科学杂志,2015,29(6):15-20. 被引量:21
  • 2苏博云,王华倩,杜志云,郑希.联合用药治疗前列腺癌的研究进展[J].医学综述,2015,21(6):999-1002. 被引量:3
  • 3Mukherji D,Pezaro CJ,Shamseddine A,et al.New treatment developments applied to elderly patients with advanced prostate cancer[J].Cancer Treat Rev,2013;39(6):578-83.
  • 4Scosyrev E,Messing EM,Mohile S,et al.Prostate cancer in the elderly:Frequency of advanced disease at presentation and disease-specific mortality[J].Cancer,2012;118(12):3062-70.
  • 5曹希亮,高江平.晚期前列腺癌药物治疗研究进展[J].解放军医药杂志,2013,25(2):59-63. 被引量:19
  • 6Basch E,Oliver TK,Vickers A,et al.Screening for prostate cancer with prostate-specific antigen testing:american society of clinical oncology provisional clinical opinion[J].J Clin Oncol,2012;30(24):3020-5.
  • 7Morgans AK,van Bommel AC,Stowell C,et al.Development of a standardized set of patient-centered outcomes for advanced prostate cancer:An international effort for a unified approach[J].Eur Urol,2015;68(5):891-8.
  • 8Heidenreich A,Bastian PJ,Bellmunt J,et al.EAU guidelines on prostate cancer.PartⅡ:treatment of advanced,relapsing,and castration-resistant prostate cancer[J].Eur Urol,2014;65(2):467-79.
  • 9Weller MA,Kupelian PA,Reddy CA,et al.Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer:does sequencing matter[J]?Clin Genitourin Cancer,2015;13(3):e183-9.
  • 10Bannuru RR,Dvorak T,Obadan N,et al.Comparative evaluation of radiation treatments for clinically localized prostate cancer:an updated systematic review[J].Ann Intern Med,2011;155(3):171-8.

二级参考文献98

  • 1叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 2朱华,邹峥.非甾体抗炎药临床作用及副作用研究新进展[J].江西医药,2007,42(3):268-271. 被引量:22
  • 3肖水源.心理卫生评定量表手册(增订版).北京:中国心理卫生杂志社,1999:31.
  • 4Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J ]. CA Cancer J Clin,2012,62 ( 1 ) : 10-29.
  • 5Tannock I, Osoba D, Stockler M R, et al. Chemothera- py with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Ca- nadian randomized trial with palliative end points [ J ]. J Clin Oncol, 1996,14(6) : 1756-1764.
  • 6Kantoff P W, Halabi S, Conaway M, et al. Hydrocorti- sone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leu- kemia group B 9182 study [ J ]. J Clin Oncol, 1999,17 (8) :2506-2513.
  • 7Holzbeierlein J, Lal P, Latulippe E, et al. Gene expres- sion analysis of human prostate eareinoma during hormo- nal therapy identifies androgen-responsive genes and mechanisms of therapy resistance [ J ]. Am J Pathol, 2004,164( 1 ) :217-227.
  • 8Locke J A, Guns E S, Lubik A A, et al. Androgen lev- els increase by intratumoral de novo steroidogenesis dur- ing progression of castration-resistant prostate cancer [ J]. Cancer Res, 2008,68 ( 15 ) :6407-6415.
  • 9Mostaghel E A, Page S T, Lin D W, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer [ J ]. Cancer Res, 2007,67(10) :5033-5041.
  • 10Attard G, Reid A, Auchus R, et al. Clinical and bio- chemical consequences of CYP17A1 inhibition with abi- raterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer[J]. J Clin Endocrinol Metab, 2012,97 ( 2 ) :507-516.

共引文献40

同被引文献13

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部